{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:34Z","timestamp":1786118914026,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1097\/cad.0b013e32830d58a6","type":"journal-article","created":{"date-parts":[[2008,8,28]],"date-time":"2008-08-28T03:08:25Z","timestamp":1219892905000},"page":"921-925","source":"Crossref","is-referenced-by-count":2,"title":["A patient with stage IV type 4 advanced gastric cancer who had a complete pathological response to short-term treatment with S-1 alone"],"prefix":"10.1097","volume":"19","author":[{"given":"Kenji","family":"Ishido","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasaburo","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikatoshi","family":"Katada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizutomo","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Saigenji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobue","family":"Futawatari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Saegusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210203","article-title":"Introduction to JGCA gastric cancer treatment guideline","year":"2004"},{"key":"R2-10-20210203","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00001813-199607000-00010","article-title":"Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators","volume":"7","author":"Shirasaka","year":"1996","journal-title":"Anti-Cancer Drugs"},{"key":"R3-10-20210203","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000012099","article-title":"Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group","volume":"58","author":"Koizumi","year":"2000","journal-title":"Oncology"},{"key":"R4-10-20210203","first-page":"811","article-title":"Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination","volume":"9","author":"Osugi","year":"2002","journal-title":"Oncol Rep"},{"key":"R5-10-20210203","first-page":"125","article-title":"Pilot study of S-1 in patients with disseminated gastric cancer","volume":"29","author":"Kitamura","year":"2003","journal-title":"Drugs Exp Clin Res"},{"key":"R6-10-20210203","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/PL00011681","article-title":"Japanese classification of gastric carcinoma, 2nd English Edition","volume":"1","year":"1998","journal-title":"Gastric Cancer"},{"key":"R7-10-20210203","first-page":"2357","article-title":"Trends in the incidence of gastrointestinal diseases in Japan","volume":"54","author":"Nagahara","year":"2005","journal-title":"Sogo Rinsho"},{"key":"R8-10-20210203","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0959-8049(98)00211-1","article-title":"Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients","volume":"34","author":"Sakata","year":"1998","journal-title":"Eur J Cancer"},{"key":"R9-10-20210203","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000012032","article-title":"The S-1 Gastrointestinal Cancer Study Group: An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers","volume":"57","author":"Sugimachi","year":"1999","journal-title":"Oncology"},{"key":"R10-10-20210203","first-page":"440","article-title":"Efficacy of TS-1 in elderly patients with gastric cancer. [In Japanese]","volume":"37","author":"Tanaka","year":"2002","journal-title":"Japan Soc Clin Oncol"},{"key":"R11-10-20210203","first-page":"2000","article-title":"Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug","volume":"5","author":"Hirata","year":"1999","journal-title":"Clin Cancer Res"},{"key":"R12-10-20210203","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00280-002-0457-z","article-title":"Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function","volume":"50","author":"Ikeda","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"R13-10-20210203","first-page":"995","article-title":"Cancer chemotherapy in patients older than 75 years old \u2013 from the aspect of clinical pharmacology","volume":"25","author":"Tanaka","year":"1998","journal-title":"Gan To Kagaku Ryoho"},{"key":"R14-10-20210203","first-page":"869","article-title":"Pharmacokinetics of 5-FU after S-1 oral administration for adjuvant chemotherapy in gastric cancer patients","volume":"34","author":"Matsumoto","year":"2007","journal-title":"Gan To Kagaku Ryoho"},{"key":"R15-10-20210203","doi-asserted-by":"crossref","first-page":"147","DOI":"10.5833\/jjgs.37.147","article-title":"Two cases of patients with advanced gastric cancer completely responding to the TS-1 treatment","volume":"37","author":"Asakawa","year":"2004","journal-title":"Jpn J Gastroenterol Surg"},{"key":"R16-10-20210203","first-page":"2165","article-title":"Complete response in an elderly patient with advanced gastric cancer treated with TS-1","volume":"31","author":"Ijuin","year":"2004","journal-title":"Gan To Kagaku Ryoho"},{"key":"R17-10-20210203","first-page":"927","article-title":"A case report of advanced gastric cancer responding to TS-1, a novel oral fluorouracil derivative","volume":"29","author":"Nakamura","year":"2002","journal-title":"Gan To Kagaku Ryoho"},{"key":"R18-10-20210203","first-page":"579","article-title":"A case report of advanced cardiac cancer showing a complete response to TS-1 as neoadjuvant chemotherapy","volume":"31","author":"Yamamoto","year":"2004","journal-title":"Gan To Kagaku Ryoho"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0b013e32830d58a6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:02:17Z","timestamp":1786035737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-200810000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e32830d58a6","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}